Positive top-line for alemtuzumab in MS despite missing second primary endpoint
This article was originally published in Scrip
Executive Summary
Top-line results from the first Phase III study of alemtuzumab (Lemtrada/Campath) in multiple sclerosis (MS) show that the trial met one primary endpoint, reduction in relapse rate compared with Rebif over the two years of the study, but failed to achieve statistical significance for the second primary endpoint, time to six month sustained accumulation of disability, as compared with Rebif (interferon beta-1a).